ARCT Earnings Date: Nov 5, 2026 (Estimated) — Arcturus Therapeutics Holdings Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ARCT's next earnings date?
Arcturus Therapeutics Holdings Inc. (ARCT) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.68 on revenue of $8.0M.
How did ARCT do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Arcturus Therapeutics Holdings Inc. posted EPS of -$0.84 versus the -$1.00 estimate, a beat of 18.4%. Revenue was $3.0M against a $3.1M estimate. The stock's 1-day post-earnings move was +21.9%.
How much does ARCT stock move after earnings?
ARCT beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.6% (up or down) in the day after earnings.
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -1.00 | -0.84 | +18.45% | $3.0M | ✅ Beat | +21.88% | +29.28% | +160.20% |
| 2026-05-07 | Q1 2026 | -1.04 | -0.95 | +8.65% | $2.1M | ✅ Beat | +3.60% | -12.02% | -20.00% |
| 2026-03-03 | Q4 2025 | -0.82 | -1.03 | -25.61% | $7.2M | ❌ Miss | -4.17% | -3.67% | -0.76% |
| 2025-11-10 | Q3 2025 | -0.98 | -0.49 | +50.00% | $17.2M | ✅ Beat | -1.25% | -23.01% | -12.64% |
| 2025-08-11 | Q2 2025 | -0.96 | -0.34 | +64.58% | $28.3M | ✅ Beat | +30.73% | +57.24% | +57.95% |
| 2025-03-06 | Q4 2024 | -0.49 | -1.11 | -126.53% | $22.8M | ❌ Miss | -8.89% | -12.96% | -42.96% |
| 2024-11-07 | Q3 2024 | -1.22 | -0.26 | +78.69% | $41.7M | ✅ Beat | +4.72% | -2.13% | +0.48% |
| 2024-05-08 | Q1 2024 | -1.19 | -1.00 | +15.97% | $38.0M | ✅ Beat | -1.54% | +6.63% | +16.94% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $3.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Grant | 70.3% | $2.1M | -45.2% | $1.8M | $3.9M | $3.8M | $3.0M |
| Collaboration Revenue | 29.7% | $880K | -96.4% | $21.0M | $25.5M | $24.5M | $14.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.